

Fluticasone/Vilanterol (Breo Ellipta) is a once-daily inhaler for asthma and COPD. Learn what it is, how it's used, who should take it, dosage information, and cost in 2026.
Fluticasone/Vilanterol is a prescription combination inhaler sold under the brand name Breo Ellipta. It's used once daily to help people with asthma or COPD (chronic obstructive pulmonary disease) breathe easier. It combines two medications — an anti-inflammatory corticosteroid and a long-acting bronchodilator — in a single inhaler.
If you or someone you know has been prescribed this medication, here's everything you need to know about what it is, how it works, how to take it, and what it costs in 2026.
Fluticasone/Vilanterol is a combination of two active ingredients:
Together, these two drugs tackle the two main problems in asthma and COPD: airway inflammation and airway tightening. You can learn more about the science in our article on how Fluticasone/Vilanterol works.
Breo Ellipta comes as a dry powder inhaler. It's manufactured by GlaxoSmithKline (GSK), and an authorized generic version has been available since 2019.
The FDA has approved Fluticasone/Vilanterol for three specific uses:
Breo Ellipta is approved as a once-daily maintenance treatment for asthma in adults. It's intended for patients whose asthma isn't well controlled with an inhaled corticosteroid alone. It is not approved for children under 18.
Important: because of the boxed warning about LABAs and asthma-related death risk, this medication should only be used for asthma when an ICS alone isn't enough.
Fluticasone/Vilanterol is used to help maintain open airways in people with COPD, including chronic bronchitis and emphysema. It helps reduce day-to-day breathing difficulties.
For COPD patients with a history of flare-ups (exacerbations), Breo Ellipta can help reduce how often these episodes occur.
Fluticasone/Vilanterol is not a rescue inhaler. It won't help during a sudden asthma attack or COPD flare-up. You still need a separate short-acting rescue inhaler like albuterol for emergencies.
Taking Breo Ellipta is straightforward:
Fluticasone/Vilanterol comes in two strengths:
Each inhaler contains 30 doses — a one-month supply.
This medication is not right for everyone. You should not use Fluticasone/Vilanterol if you:
Use with caution if you have:
If you're pregnant or breastfeeding, talk to your doctor. Fluticasone/Vilanterol is Pregnancy Category C, meaning it should only be used if the benefit outweighs the potential risk.
Be sure to tell your doctor about all other medications you take. Fluticasone/Vilanterol has important drug interactions, particularly with strong CYP3A4 inhibitors, beta-blockers, and other long-acting bronchodilators.
Cost is a real concern for many patients. Here's what you can expect:
Most commercial insurance plans and Medicare Part D cover Breo Ellipta, though it's often on a higher formulary tier (Tier 3 or Tier 4). Copays typically range from $30–$75 with insurance. Some plans may require prior authorization or step therapy (trying a less expensive inhaler first).
For a complete guide, see how to save money on Fluticasone/Vilanterol.
Fluticasone/Vilanterol (Breo Ellipta) is a well-established, once-daily inhaler that makes managing asthma and COPD simpler. With just one puff a day, it addresses both inflammation and airway tightening — the two key problems in these conditions.
If you've been prescribed Fluticasone/Vilanterol, make sure you understand what side effects to watch for and how to use the inhaler properly. If you're having trouble finding it at your pharmacy, Medfinder can help you check stock near you.
You focus on staying healthy. We'll handle the rest.
Try Medfinder Concierge FreeMedfinder's mission is to ensure every patient gets access to the medications they need. We believe this begins with trustworthy information. Our core values guide everything we do, including the standards that shape the accuracy, transparency, and quality of our content. We’re committed to delivering information that’s evidence-based, regularly updated, and easy to understand. For more details on our editorial process, see here.